Vertex Pharmaceuticals· @VertexPharma · X·· 8 天前精选AI 评分62
AI 导读
Vertex宣布其在研疗法用于APOL1介导肾病的2b期AMPLIFIED研究取得积极结果，同时2/3期AMPLITUDE试验已完成入组。公司未在帖文中披露具体疗效数据，更多信息见其新闻稿链接。
推荐理由
原文披露了APOL1介导肾病在研疗法的2b期积极结果与2/3期入组完成，可据此了解该靶点研发进度。
正文
We announced positive Phase 2b AMPLIFIED results and completion of enrollment in the Phase 2/3 AMPLITUDE trial for people living with APOL1-mediated kidney disease.
Learn more: https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study
来源：Vertex Pharmaceuticals · x.com